Gene Expression Regulation, Neoplastic
"Gene Expression Regulation, Neoplastic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.
| Descriptor ID |
D015972
|
| MeSH Number(s) |
G05.308.370
|
| Concept/Terms |
Gene Expression Regulation, Neoplastic- Gene Expression Regulation, Neoplastic
- Regulation of Gene Expression, Neoplastic
- Regulation, Gene Expression, Neoplastic
- Neoplastic Gene Expression Regulation
|
Below are MeSH descriptors whose meaning is more general than "Gene Expression Regulation, Neoplastic".
Below are MeSH descriptors whose meaning is more specific than "Gene Expression Regulation, Neoplastic".
This graph shows the total number of publications written about "Gene Expression Regulation, Neoplastic" by people in this website by year, and whether "Gene Expression Regulation, Neoplastic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1996 | 1 | 0 | 1 |
| 1997 | 1 | 1 | 2 |
| 1998 | 0 | 2 | 2 |
| 2000 | 1 | 0 | 1 |
| 2001 | 3 | 0 | 3 |
| 2002 | 1 | 4 | 5 |
| 2003 | 0 | 2 | 2 |
| 2004 | 2 | 1 | 3 |
| 2005 | 1 | 3 | 4 |
| 2006 | 2 | 2 | 4 |
| 2007 | 5 | 3 | 8 |
| 2008 | 2 | 3 | 5 |
| 2009 | 2 | 1 | 3 |
| 2010 | 1 | 4 | 5 |
| 2011 | 2 | 3 | 5 |
| 2012 | 0 | 2 | 2 |
| 2013 | 1 | 1 | 2 |
| 2014 | 0 | 3 | 3 |
| 2015 | 4 | 4 | 8 |
| 2016 | 0 | 2 | 2 |
| 2017 | 1 | 4 | 5 |
| 2018 | 1 | 3 | 4 |
| 2019 | 1 | 2 | 3 |
| 2020 | 0 | 3 | 3 |
| 2021 | 1 | 1 | 2 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Gene Expression Regulation, Neoplastic" by people in Profiles.
-
RBL2/DREAM-mediated repression of the Aurora kinase A/B pathway determines therapy responsiveness and outcome in p53 WT NSCLC. Sci Rep. 2022 01 20; 12(1):1049.
-
Identification of Novel Therapeutic Targets for Fibrolamellar Carcinoma Using Patient-Derived Xenografts and Direct-from-Patient Screening. Cancer Discov. 2021 10; 11(10):2544-2563.
-
Comparative analysis of 1152 African-American and European-American men with prostate cancer identifies distinct genomic and immunological differences. Commun Biol. 2021 06 03; 4(1):670.
-
Bone metastatic breast cancer cells display downregulation of PKC-? with enhanced glutamine metabolism. Gene. 2021 Apr 05; 775:145419.
-
Deep learning prediction of BRAF-RAS gene expression signature identifies noninvasive follicular thyroid neoplasms with papillary-like nuclear features. Mod Pathol. 2021 05; 34(5):862-874.
-
Loss of STAT6 leads to anchorage-independent growth and trastuzumab resistance in HER2+ breast cancer cells. PLoS One. 2020; 15(6):e0234146.
-
Expression and function of voltage gated proton channels (Hv1) in MDA-MB-231 cells. PLoS One. 2020; 15(5):e0227522.
-
HDAC6-dependent ciliophagy is involved in ciliary loss and cholangiocarcinoma growth in human cells and murine models. Am J Physiol Gastrointest Liver Physiol. 2020 06 01; 318(6):G1022-G1033.
-
COMMD3:BMI1 Fusion and COMMD3 Protein Regulate C-MYC Transcription: Novel Therapeutic Target for Metastatic Prostate Cancer. Mol Cancer Ther. 2019 11; 18(11):2111-2123.
-
O-GlcNAc modification of Sox2 regulates self-renewal in pancreatic cancer by promoting its stability. Theranostics. 2019; 9(12):3410-3424.